In addition, since the activation of CDK4 in PC is due to either the upregulation of cyclin D1 or the loss of p16INK4a (Figure 9), subgrouping patients based on cyclin D and p16INK4a levels could show varying and important differences in response levels to CDK4/6i. Here, CDKN2A is linked to pachyonychia congenita.